AZTR.US Azitra Inc

Healthcare Biotechnology USA Stocks
0.6084 USD
Close of Nov 13, 2026
0.5200 3.91
Market cap
USD 3.69M
P/E
-
P/B
0.55x
ROE
-198.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AZTR.US undervalued?

Graham number

The Graham number of Azitra Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Azitra Inc fundamental analysis

No fundamental analysis for Azitra Inc yet.

Azitra Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Azitra Inc

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; AT…

Full company profile